MapLight Therapeutics (MPLT) EPS (Basic) (2024 - 2026)
MapLight Therapeutics (MPLT) posted EPS (Basic) of -$9.35 for Q4 2025, up 78.28% sequentially from -$43.06 in Q3 2025, and up 68.08% YoY from -$5.57 in Q4 2024.
Powered by 
Analysis
MapLight Therapeutics (MPLT) EPS (Basic) (2024 - 2026) Analysis & Trends
MapLight Therapeutics has reported EPS (Basic) for 2 years, with the latest figure at -$9.35 in Q4 2025.
- Quarterly EPS (Basic) rose 68.08% year-over-year to -$9.35 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$18.08 (changed N/A YoY) and the FY2025 annual result came in at -$20.3, up 83.57% from the prior year.
- EPS (Basic) climbed to -$9.35 in Q4 2025 per MPLT's latest filing, from -$43.06 in the prior quarter.
- Over five years, EPS (Basic) peaked at -$9.35 in Q4 2025 and troughed at -$43.06 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 7.70 |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -1.96 |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | -3.06 |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 2.12 |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 1.23 |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 0.18 |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -0.06 |
| 10 | MapLight Therapeutics | 628.32 Mn | 628.32 Mn | - | -1.35 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.35 |
| Dec 31, 2025 | -9.32 |
| Sep 30, 2025 | -37.86 |
| Jun 30, 2025 | -39.28 |
| Dec 31, 2024 | -29.72 |
| Sep 30, 2024 | -26.13 |